Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer

Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

United States ,Germany ,Italy ,Milan ,Lombardia ,Munich ,Bayern ,Scintomics Gmb ,Davide Gauden ,Eugene Teoh ,Technical University Of Munich ,Nuclear Medicine ,Drug Administration ,Bracco Group ,Earth Diagnostics ,New Drug Application ,Prostate Specific Membrane Antigen Targeted ,Blue Earth ,Chief Executive Officer ,Blue Earth Diagnostic Phase ,Technical University ,Chief Medical Officer ,Radiohybrid Prostate Specific Membrane Antigen ,Prostate Specific Membrane Antigen ,Blue Earth Diagnostics ,Scintomics Gmbh ,Emission Tomography ,Prostate Specific Antigen ,Earth Diagnostic ,Bracco Imaging ,Interventional Radiology ,Cardiac Catheterization ,Magnetic Resonance Imaging ,Contrast Enhanced Ultrasound ,Blue Earth Therapeutics ,Resume ,Careers ,Lue Earth Diagnostics Announces Fda Acceptance Of New Drug Application For 18f Rhpsma 7 3 ,A Radiohybrid Prostate Specific Membrane Antigen Targeted Pet Imaging Agent For Cancer ,Iospace ,Advice ,